Catalog No.
DHC82401
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Chimeric
Isotype
IgG4-kappa
Clonality
Monoclonal
Target
MAPTL, Paired helical filament-tau, MTBT1, Microtubule-associated protein tau, TAU, Neurofibrillary tangle protein, MAPT, PHF-tau
Concentration
2.46 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P10636
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
BMS-986168, IPN-002, huIPN-002, CAS: 1788032-39-2
Clone ID
Gosuranemab
Alzheimer's disease: Recent treatment strategies, PMID: 32941929
Characterization of tau binding by gosuranemab, PMID: 32991997
Tau immunotherapy is associated with glial responses in FTLD-tau, PMID: 33950293
Immunotherapy in progressive supranuclear palsy, PMID: 32657895
Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial, PMID: 34385707
Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial, PMID: 31122495
The science does not yet support regulatory approval of amyloid-targeting therapies for Alzheimer's disease based solely on biomarker evidence., PMID:40243238
Lecanemab for early Alzheimer's disease: Appropriate use recommendations from the French federation of memory clinics., PMID:40011173
Comparative the efficacy and safety of Gosuranemab, Semorinemab, Tilavonemab, and Zagotenemab in patients with Alzheimer's disease: a systematic review and network meta-analysis of randomized controlled trials., PMID:39945003
2024 AA criteria for Alzheimer's disease diagnosis: Mainly anchored at Aβ not tau., PMID:39470319
Scenarios for the long-term efficacy of amyloid-targeting therapies in the context of the natural history of Alzheimer's disease., PMID:39073291
What is Alzheimer's disease? An analysis of nosological perspectives from the 20th and 21st centuries., PMID:38618742
Prognostic and Predictive Factors in Early Alzheimer's Disease: A Systematic Review., PMID:38405341
Posterior cortical atrophy: new insights into treatments and biomarkers for Alzheimer's disease., PMID:38267172
TANGO: a placebo-controlled randomized phase 2 study of efficacy and safety of the anti-tau monoclonal antibody gosuranemab in early Alzheimer's disease., PMID:38012285
Analysis of clinical failure of anti-tau and anti-synuclein antibodies in neurodegeneration using a quantitative systems pharmacology model., PMID:37658103
Passive tau-based immunotherapy for tauopathies., PMID:37620094
Key questions for the evaluation of anti-amyloid immunotherapies for Alzheimer's disease., PMID:37389302
Dementia prevention in memory clinics: recommendations from the European task force for brain health services., PMID:36895446
Author Correction: Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial., PMID:36253611
PBPK-PD modeling for the preclinical development and clinical translation of tau antibodies for Alzheimer's disease., PMID:36120380
Development of a cognitive composite for measuring change in progressive supranuclear palsy., PMID:34736158
Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial., PMID:34385707
Tau immunotherapy is associated with glial responses in FTLD-tau., PMID:33950293
Characterization of tau binding by gosuranemab., PMID:32991997
Alzheimer's disease: Recent treatment strategies., PMID:32941929
Immunotherapy in progressive supranuclear palsy., PMID:32657895
Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial., PMID:31122495
For research use only. Not for human or drug use.
